Oncology Dominates Japan Approvals, Though Overall Tally Is Lower
Executive Summary
Although it approved fewer new products last fiscal year, Japan granted access to a number of important new therapies, including in oncology and several for the first time worldwide, helped by continuing reforms at its regulatory body.